Drug Profile


Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; resTORbio
  • Class 3-ring heterocyclic compounds; Acetonitriles; Antineoplastics; Antivirals; Benzenesulfonates; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza virus infections; Respiratory tract infections
  • Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 08 May 2017 Phase-II clinical trials in Respiratory tract infections (In the elderly, Monotherapy) in New Zealand (PO) (ACTRN12617000468325p)
  • 08 May 2017 Phase-II clinical trials in Respiratory tract infections (Combination therapy, In the elderly) in New Zealand (PO) (ACTRN12617000468325p)
  • 04 Apr 2017 resTORbio plans a phase II trial for Respiratory tract infections (Combination therapy, Monotherapy) in New Zealand (ACTRN12617000468325p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top